Effective itch relief through inhibition of the IL-31 signaling pathway

The vicious circle of itching and scratching is a central element in both prurigo nodularis (PN) and atopic dermatitis (AD). Interleukin (IL)-31, often referred to as the “itch cytokine”, has been identified as a key cytokine in this process. Nemolizumab, a specific antagonist of the IL-31 receptor, enables targeted blockade of this signaling pathway. Current study data confirm the therapeutic potential in PN and AD.